---
document_datetime: 2025-11-10 10:14:58
document_pages: 9
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/oyavas-epar-procedural-steps-taken-scientific-information-after-authorisation-archived_en.pdf
document_name: oyavas-epar-procedural-steps-taken-scientific-information-after-authorisation-archived_en.pdf
version: success
processing_time: 5.6325958
conversion_datetime: 2025-12-26 20:26:39.134481
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Oyavas

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                             | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IB/0035              | B.II.b.4.f - Change in the batch size (including batch size ranges) of the finished product - The scale for a biological/immunological medicinal product is increased/decreased without process change (e.g. duplication of line) | 14/11/2024                          | n/a                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|             | - Implementation of changes foreseen in an change management protocol - For a medicinal product                                                                                                                                                                                                                                                                                | 24/09/2024   | n/a        |                       | IB/0034 B.I.e.5.c approved biological/immunological   |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------------|-------------------------------------------------------|
| IB/0033     | B.I.e.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product                                                                                                                                                                                                                                    | 17/07/2024   | n/a        |                       |                                                       |
| IAIN/0032   | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                             | 26/06/2024   | n/a        |                       |                                                       |
| IAIN/0031/G | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - batch control/testing | 22/04/2024   | 14/04/2025 | SmPC, Annex II and PL | Not including                                         |
| IB/0029     | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                                                                   | 06/03/2024   | n/a        |                       |                                                       |
| IB/0027     | B.I.e.4.b - Changes to an approved change management protocol - Minor changes that do not change the strategy defined in the protocol                                                                                                                                                                                                                                          | 23/02/2024   | n/a        |                       |                                                       |

<div style=\"page-break-after: always\"></div>

| IB/0028/G   | This was an application for a group of variations. B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.III.2.a.2 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - Excipient/AS starting material   | 19/01/2024   | n/a        |             |
|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|
| IB/0026     | B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 19/12/2023   | n/a        |             |
| IB/0025     | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 29/09/2023   | 19/10/2023 | SmPC and PL |

<div style=\"page-break-after: always\"></div>

| II/0022   | B.I.e.2 - Introduction of a post approval change management protocol related to the AS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 14/09/2023   | n/a   |               |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|---------------|
| IB/0024/G | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor approved test procedure | 11/07/2023   | n/a   | changes to an |

<div style=\"page-break-after: always\"></div>

|                   | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                                         |            |            |             |                                                                                                                                          |
|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0023           | B.I.e.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product                                                                                                                                                                                                 | 04/07/2023 | n/a        |             |                                                                                                                                          |
| IB/0021           | B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation                                                                                                                                                                                                                                 | 08/05/2023 | n/a        |             |                                                                                                                                          |
| IB/0020           | B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol                                                                                                                                                         | 28/04/2023 | 19/10/2023 | SmPC        | SmPC was updated to reflect extension of shelf life.                                                                                     |
| II/0019           | B.I.e.2 - Introduction of a post approval change management protocol related to the AS                                                                                                                                                                                                                                                      | 09/02/2023 | n/a        |             |                                                                                                                                          |
| PSUSA/403/2 02202 | Periodic Safety Update EU Single assessment - bevacizumab                                                                                                                                                                                                                                                                                   | 13/10/2022 | 09/12/2022 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/403/202202. |
| IB/0018/G         | This was an application for a group of variations. B.I.e.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product | 20/10/2022 | n/a        |             |                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

| IB/0017/G   | This was an application for a group of variations. B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation             | 11/10/2022   | n/a   |                                         |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-----------------------------------------|
| IB/0015     | B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                      | 26/08/2022   | n/a   |                                         |
|             | This was an application for a group of variations. B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting | 25/08/2022   | n/a   | IB/0016/G material/intermediate/reagent |

<div style=\"page-break-after: always\"></div>

|           | significant specification parameter (e.g. deletion of an obsolete parameter) B.III.2.a.2 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - Excipient/AS starting material                                                                                                                                                                                                                                 |            |            |             |                                                                                       |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------------------------------------------------------------------------------------|
| IB/0013   | B.II.g.4.b - Changes to an approved change management protocol - Minor changes that do not change the strategy defined in the protocol                                                                                                                                                                                                                                                                                                                                                                                  | 03/08/2022 | n/a        |             |                                                                                       |
| IA/0014/G | This was an application for a group of variations. B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information | 21/07/2022 | n/a        |             |                                                                                       |
| IA/0012   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 04/07/2022 | n/a        |             |                                                                                       |
| IB/0011/G | This was an application for a group of variations. A.6 - Administrative change - Change in ATC Code/ATC Vet Code C.I.2.a - Change in the SPC, Labelling or PL of a                                                                                                                                                                                                                                                                                                                                                      | 04/07/2022 | 09/12/2022 | SmPC and PL | To update sections 4.2 and 6.6 of the SmPC to reinstate the statement 'do not shake'. |

<div style=\"page-break-after: always\"></div>

|           | generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                   |            |            |                        |            |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|------------|
| II/0009/G | This was an application for a group of variations. B.I.e.2 - Introduction of a post approval change management protocol related to the AS B.II.g.2 - Introduction of a post approval change protocol related to the finished product                         | 02/06/2022 | n/a        |                        | management |
| N/0008    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                             | 17/03/2022 | 09/12/2022 | Labelling and PL       |            |
| IA/0007   | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                          | 07/02/2022 | n/a        |                        |            |
| IB/0006   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 26/01/2022 | 09/12/2022 | SmPC, Labelling and PL |            |
| II/0004   | B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a                           | 13/01/2022 | n/a        |                        |            |

<div style=\"page-break-after: always\"></div>

|           | biological AS                                                                                                                                                                                                                                                                                                                                                    |            |     |                              |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------------------------|
| IAIN/0005 | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                               | 17/11/2021 | n/a |                              |
| II/0003/G | This was an application for a group of variations. B.II.b.4.c - Change in the batch size (including batch size ranges) of the finished product - The change requires assessment of the comparability of a biological/immunological medicinal product or a new bioequivalence study B.II.b.3.z - Change in the manufacturing process of product - Other variation | 16/09/2021 | n/a | the finished or intermediate |
| IB/0002   | B.I.e.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product                                                                                                                                                                                                                      | 22/07/2021 | n/a |                              |
| IAIN/0001 | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                               | 03/05/2021 | n/a |                              |